Effect of 3 months of doxazosin therapy on T-cell subsets in type 2 diabetic patients.
Author(s): Macsai E, Cseh A, Budai G, Meszaros G, Vasarhelyi B, Fischer K, Szabo A, Treszl A
Affiliation(s): Department of Internal Medicine, Csolnoky Hospital, Veszprem, Hungary.
Publication date & source: 2009-11, J Int Med Res., 37(6):1982-7.
Publication type: Clinical Trial; Research Support, Non-U.S. Gov't
Doxazosin, an alpha(1)-adrenergic receptor inhibitor, is commonly administered to patients with type 2 diabetes, hypertension and nephropathy. The impact of 3 months' doxazosin therapy on the prevalence of activated and regulatory T lymphocytes was analysed in this pilot study of men with type 2 diabetes (n = 10) who received doxazosin 4 mg/day in addition to their ongoing therapy. The prevalence of CD4(+), CD8(+), CD25(+) and CD69(+) cells at baseline and after 3 months of add-on therapy was determined. The prevalence of regulatory T-cells was detected by two different approaches: forkhead box P3 (FoxP3) positivity; and the number of CD4(+)CD25(+high) cells. During 3 months of doxazosin therapy, patients' blood pressure, blood glucose control and lipid profiles all significantly improved. Simultaneously, the prevalence of activated T-cells (CD4(+)CD69(+) and CD8(+)CD69(+) cells) decreased, whereas that of regulatory T-cells increased. These results indicate an immunomodulatory action of doxazosin in type 2 diabetic patients.
|